Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | LGMN | Q99538 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72773 | 1.00 | MAPT (0.45) | MAPTHRH3LGMNALDH1A1GAA | |
| SCHEMBL73430 | 0.83 | HRH3 (0.46) | MAPTHRH3ALDH1A1POLBHTT | |
| SCHEMBL73431 | 0.83 | HRH3 (0.46) | MAPTHRH3ALDH1A1POLBHTT | |
| SCHEMBL71447 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1POLBHTTKDM4E | |
| SCHEMBL72207 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1POLBHTTKDM4E | |
| SCHEMBL71446 | 0.82 | ALDH1A1 (0.48) | MAPTALDH1A1POLBHTTKDM4E | |
| SCHEMBL1648624 | 0.81 | MAPT (0.64) | MAPTLGMNALDH1A1GAAPOLB | |
| Hydrochloric Acid SCHEMBL72208 | 0.81 | ALDH1A1 (0.50) | MAPTALDH1A1POLBHTTKDM4E | |
| Hydrochloric Acid SCHEMBL72206 | 0.81 | ALDH1A1 (0.50) | MAPTALDH1A1POLBHTTKDM4E | |
| SCHEMBL73440 | 0.76 | ALDH1A1 (0.43) | MAPTALDH1A1POLBHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAPT 4775/4885HRH3 314/4885LGMN 3510/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | MAPT 4773/4885HRH3 372/4885LGMN 3396/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAPT 4795/4885HRH3 247/4885LGMN 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.